<DOC>
	<DOCNO>NCT00181675</DOCNO>
	<brief_summary>This double-blind , placebo-controlled , study use daily dos 24 mg/ day Galantamine HBr treatment adult meet DSM-IV criterion childhood-onset ADHD . Specific hypotheses follow : Hypothesis 1 : ADHD symptomatology adult DSM-IV ADHD responsive acute Galantamine HBr treatment . Hypothesis 2 : Galantamine HBr -associated improvement ADHD symptomatology adult translate improve functional capacity ( neuropsychological , social , occupational ) well increase quality life throughout acute treatment . Hypothesis 3 : Galantamine HBr treatment safe well tolerate reflect low drop rate absence major difference placebo .</brief_summary>
	<brief_title>A Double-Blind Comparison Galantamine HBr Placebo Adults With Attention Deficit Hyperactivity Disorder</brief_title>
	<detailed_description>Galantamine HBr , tertiary alkaloid , competitive reversible inhibitor acetylcholinesterase indicate slow deterioration cognitive impairment Alzheimer 's Disease . Initial anecdotal data suggest promising role Galantamine HBr treatment ADHD . We propose study test safety efficacy Galantamine HBr therapy adult ADHD . We test Galantamine HBr -associated improvement ADHD symptomatology translate improve cognitive functional capacity ( social occupational ) well increase quality life . The propose study include 1 ) use 12-week design document response rate 2 ) assessment impact Galantamine HBr functional capacity ( quality life , psychosocial function ) cognition , 3 ) careful assessment safety tolerability .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>1 . Male outpatient 18 58 year age ( inclusive ) . 2 . Females 18 58 year age ( inclusive ) reliable adequate birth control . 3 . Subjects DSMIV diagnosis childhood onset AttentionDeficit/Hyperactivity Disorder ( ADHD ) , manifest clinical evaluation confirm structured interview . 4 . Subjects score 24 great ADHD Rating Scale . 1 . Any current , nonADHD Axis I psychiatric condition clinical significance . 2 . Baseline HamD &gt; 16 , BDI &gt; 19 , and/or HamA &gt; 21 . 3 . Any clinically significant chronic medical condition , specifically cardiovascular , gastrointestinal , pulmonary , genitourinary , metabolic , endocrine disorder , hepatic renal impairment . 4 . Clinically significant abnormal baseline laboratory value . 5 . I.Q . &lt; 75 . 6 . Organic brain disorder . 7 . Subjects history current seizure disorder . 8 . Pregnant and/or nursing female . 9 . Clinically unstable psychiatric condition ( i.e . suicidal behavior , psychosis ) . 10 . Subjects currently ( within past 6 month ) know abuse dependent drug , include alcohol . 11 . Subjects psychotropic medication , exception SSRIs . 12 . Subjects history intolerance nonresponse cholinergic agent determine clinician . 13 . Subjects history peptic ulcer disease , gastroesophageal reflux disease , GI disorder . 14 . Subjects history bradyarrythmias . 15 . Subjects asthma . 16 . Subjects ketoconazole .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>58 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Adult</keyword>
	<keyword>ADHD</keyword>
	<keyword>galantamine</keyword>
	<keyword>double-blind</keyword>
</DOC>